332 related articles for article (PubMed ID: 32621407)
1. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Kagami S; Kishi Y; Hino H
J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H
Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
Ghandi N; Daneshmand R; Hatami P; Abedini R; Nasimi M; Aryanian Z; Vance TM
Int Immunopharmacol; 2021 Oct; 99():107971. PubMed ID: 34298402
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
Ibrahim SA; Esawy AM; Abdelshafy AS
Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076
[TBL] [Abstract][Full Text] [Related]
6. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based on clinical studies.
Behrangi E; Roohaninasab M; Sadeghzadeh-Bazargan A; Najar Nobari N; Ghassemi M; Seirafianpour F; Goodarzi A; Dodangeh M
J Cosmet Dermatol; 2022 Jul; 21(7):2727-2741. PubMed ID: 34606676
[TBL] [Abstract][Full Text] [Related]
8. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
[TBL] [Abstract][Full Text] [Related]
9. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
Chua SH; Goh CL; Ang CB
Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.
Wu SZ; Wang S; Ratnaparkhi R; Bergfeld WF
Pediatr Dermatol; 2018 Nov; 35(6):817-820. PubMed ID: 30338548
[TBL] [Abstract][Full Text] [Related]
11. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
12. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
13. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
14. Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study.
Thuangtong R; Suvansuthi S; Maneeprasopchoke P; Sukakul T; Techakajornkeart R; Chaweekulrat P; Wongdama S; Triwongwaranat D
Int J Trichology; 2022; 14(3):91-96. PubMed ID: 35755959
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
Starace M; Vezzoni R; Alessandrini A; Bruni F; Carpanese MA; Misciali C; Sechi A; Piraccini BM
Dermatol Ther; 2021 Sep; 34(5):e15096. PubMed ID: 34390608
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population.
Zafrir Y; Tantuco K; Tangtatco AJA; Ho N
J Cutan Med Surg; 2023; 27(5):449-453. PubMed ID: 37559401
[TBL] [Abstract][Full Text] [Related]
17. Topical therapy of alopecia areata with squaric acid dibutylester.
Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
[TBL] [Abstract][Full Text] [Related]
18. Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
Özdemir M; Balevi A
Pediatr Dermatol; 2017 Mar; 34(2):128-132. PubMed ID: 28044367
[TBL] [Abstract][Full Text] [Related]
19. Topical immunotherapy in alopecia areata.
Singh G; Lavanya M
Int J Trichology; 2010 Jan; 2(1):36-9. PubMed ID: 21188022
[TBL] [Abstract][Full Text] [Related]
20. Determination of the sildenafil effect on alopecia areata in childhood: An open-pilot comparison study.
Sarifakioglu E; Degim IT; Gorpelioglu C
J Dermatolog Treat; 2006; 17(4):235-7. PubMed ID: 16971319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
